

1 **Highlights**

- 2 • A sample injection strategy in CCC
- 3 • Injection process as two separate stages: injection and post-injection
- 4 • “The best solvent” approach to sample solution
- 5 • Loading increase by 1.8 times from 0.66 g/100mL V_c to 1.2 g/100mL V_c .
- 6 • Throughput increase of 46.5% from 3.1 g/h to 4.5 g/h and in yield from 82.0% to
- 7 85.5% with honokiol purity of >99% and magnolol purity of <0.1%.

8

9 **Sample injection strategy to increase throughput in counter-current**
10 **chromatography: case study of Honokiol purification**

11 Aihua Peng^a, Peter Hewitson^b, Haoyu Ye^a, Liansuo Zu^c, Ian Garrard^b, Ian Sutherland^b,
12 Lijuan Chen^{a,*}, Svetlana Ignatova^{b,**}

13
14 ^a State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
15 and Collaborative innovation Centre for Bio therapy, Chengdu 610041, China

16 ^b Advanced Bioprocessing Centre, Institute of Environment, Health and Societies, Brunel
17 University London, Uxbridge, UB8 3PH, UK

18 ^c Department of Pharmacology and Pharmaceutical Sciences, School of Medicine, Tsinghua
19 University and Collaborative Innovation Centre for Biotherapy, Beijing 100084, China

20
21 Corresponding authors:

22 E-mail addresses: chenlijuan125@163.com (L. Chen), svetlana.ignatova@brunel.ac.uk (S.
23 Ignatova).

24
25 **Abstract**

26 Counter-current chromatography (CCC) has been widely used as a preparative separation
27 method to purify natural products from plant extracts and fermentation broths. Traditionally,
28 throughput optimization in CCC has focused on sample concentration and sample volume.
29 In this paper sample injection was considered as consisting of three variables: injection flow
30 rate, post-injection flow rate and sample solvent. The effects of these parameters were studied
31 using a honokiol purification from a *Magnolia officinalis* bark extract as a case study aiming
32 to achieve the highest throughput/yield ratio for greater than 99% purity of this potential anti-
33 cancer drug obtained for submission to the Chinese FDA. An injection method was
34 established that increased the throughput of honokiol by 46.5% (from 3.05 g/h to 4.47 g/h),
35 and decreased the solvent consumption of mobile phase and stationary phase per gram of
36 honokiol by 40.0% (from 0.68 L/g to 0.41 L/g) and 48.4% (from 0.40 L/g to 0.21 L/g)
37 respectively. These results show the importance of understanding the whole injection process
38 when optimizing a given CCC separation.

39 **Key words:** Counter-current chromatography, CCC, sample injection, honokiol, magnolol,
40 sample loading, throughput

41 **1. Introduction**

42 *Magnolia officinalis* Rehd. et Wils. (Houpu in Chinese) bark extract is a traditional Chinese
43 medicine, which has been widely used to treat many diseases such as thrombotic stroke,
44 typhoid fever, anxiety and nervous disturbance [1]. Recent research has found that the extract
45 of *Magnolia officinalis* bark has other bioactive effects such as prevention and treatment of
46 Alzheimer's disease [2]; pneumonia [3] and its anti-neuroinflammatory & anti-amyloidogenic
47 effects [4]. Honokiol (HK) is one of the major bioactive ingredients in *Magnolia officinalis*
48 bark extract. Previous research demonstrated diverse bioactivities of honokiol, including
49 inducing apoptosis and inhibiting growth of several tumor cell lines [5-7], crossing the blood-
50 brain barrier and inhibiting brain tumours [8], anti-angiogenesis activities in vitro and in vivo
51 [9]. Due to its significant anti-tumour activity, our team has performed a pre-clinical research
52 study and as a result, submitted a new drug application to the China Food and Drug
53 Administration. In preparing for clinical trials, it is important to establish the most efficient
54 and economical process for production of the required amount of HK at a minimum of 80%

55 yield and at a minimum of 99% purity with the magnolol (MG, honokiol's isomer) content
56 <0.1%.

57 To deliver enough material for the pre-clinical HK research study, different methods to
58 produce HK were considered. Firstly, the synthetic route has been tried as the most common
59 approach in the pharmaceutical industry. The procedure proposed in [10] required the use of
60 a heavy metal based catalyst and additional purification steps with low final yield. Therefore,
61 the next approach was based on the use of a traditional extraction of HK from Magnolia bark
62 followed by a single purification step. For the latter preparative HPLC, normal phase
63 preparative middle pressure column chromatography and counter-current chromatography
64 (CCC) were tested. It was found that CCC was the most efficient method for our sample (data
65 not shown). CCC is a liquid-liquid partition chromatography, which was introduced by Ito
66 [11] and has been widely used for natural product purification [12-15]. The advantage of
67 having a high ratio of liquid stationary phase retained in the column makes CCC an excellent
68 preparative separation method [13] because of its high sample loading capacity. This paper
69 will be focusing on CCC as an alternative separation method for HK because of its high
70 throughput and good repeatability characteristics as well as being more environmentally
71 friendly with lower solvent consumption. For any preparative separation method, throughput
72 is an important evaluation parameter at a set purity and yield, which has been mentioned only
73 in a few papers [1, 16, 17]. It has been demonstrated before by the authors [1] that CCC can
74 successfully purify HK with a hexane-ethyl acetate-methanol-water (5:2:5:2) two-phase
75 system at preparative and pilot scales. However, in this study, to reduce the toxicity of the
76 solvent system, methanol was replaced with ethanol, which consequently changed the
77 physico-chemical properties of both liquid phases including the polarity difference between
78 them.

79 There have been few publications focussing on optimising sample loading. Walter Conway
80 in his book on Countercurrent Chromatography mentioned that "the upper limit of sample
81 size is determined primarily by solubility" and hinted that better resolution might be obtained
82 by injecting the sample dissolved equally in each phase [18], but was very much working in
83 the linear range. Berthod [19] was perhaps the first to explore beyond the linear range when
84 scaling up separations and pushed his sample loading so much that the mix became very
85 viscous and resulted in plug flow with total loss of stationary phase. He over came this by
86 varying the flow regime around sample injection – in his case 17 minutes at 4 mL/min for
87 the sample in MP followed by 30 mins of MP from T>H. The flow was then stopped and
88 reversed (H>T) for 10 mins "to dissolved the plug of injected phase" before once more
89 reversing the flow after a short 5 minute period of no flow and re-equilibration. Berthod
90 therefore demonstrated in a one-off experiment the effectiveness of modifying flow regimes
91 when injecting and also demonstrated the loss of stationary phase with high sample loading.
92 Much later, Zhao and He [20] showed that there was a good correlation between predictions
93 of peak height and width for varying sample loads using the Van Deemter theory, but they
94 were working in the linear range.

95 Finally, there have been excellent studies on optimising the injection step when scaling up
96 for production using centrifugal partition chromatography (CPC) [21] and then putting it into
97 practice [22]. It should be noted that CPC is considered overall as a hydrostatic process
98 (despite hydrodynamic cascade mixing in each chamber) as when the flow stops the
99 stationary phase remains trapped in each chamber. The high performance countercurrent
100 chromatography process (HPCCC) we are describing in this paper is a hydrodynamic process
101 where if the flow stops the upper phase moves to the head end of the column and the lower
102 phase moves to the tail (countercurrent). Therefore as Luc Marchal [21] says "The flow

103 pattern, mass transfer and solute resident time distribution in CPC is fundamentally different
104 from CCC". Nevertheless flooding (loss of stationary phase) and possibly viscous fingering
105 can occur in both but will require different approaches to overcome them as Berthod [19]
106 demonstrates.

107 Therefore, in the present work, a complete stationary phase retention study and the effect of
108 different CCC operational parameters on throughput, purity and yield was systematically
109 studied. Also various scenarios for sample injection have been investigated, building on these
110 previous studies, aiming for much higher sample loading on a 1 L lab scale CCC instrument.

111

112 **2. Experiments**

113 *2.1 Reagents*

114 Solvents used for CCC were of analytical grade and for HPLC analysis were HPLC grade
115 from Fisher Chemicals (Loughborough, UK). HPLC grade water was purified by a Purite
116 Select Fusion pure water system (Thame, UK).

117 *2.2 Apparatus*

118 A Midi-DE CCC centrifuge (Dynamic Extractions Tredegar, UK) fitted with 4 mm I.D.
119 preparative columns made of polyfluoroalkoxy tubing (PFA) with volumes of 459 and 453
120 mL was used to perform the counter-current extractions. The distance between the column
121 axis and central axis of the planetary centrifuge for these columns was 11 cm with a β value
122 range of 0.52-0.86. A Knauer K-1800 HPLC pump (Berlin, Germany) was used to pump
123 solvent into columns. A Knauer K-2501 spectrophotometer with a preparative flow cell was
124 operated at 254 nm to monitor the elution.

125 HPLC was performed on a Waters Alliance 2695 separation module (with Empower software)
126 connected to a Waters 2996 photodiode array (PDA) detector (210-400 nm) using a Sunfire
127 C18 column (150 mm \times 4.6 mm I.D., 5 μ m) (Waters, Milford, MA, USA).

128 *2.3 Crude preparation*

129 The dry bark of *Magnolia officinalis* (10 Kg, obtained from Xinhehua Traditional Chinese
130 Medicine Ltd.) was mixed with 1 Kg calcium oxide and 200L water in a multi-functional
131 extracting tank. After 24 hours, the extract was filtered and the pH of the solvent was
132 adjusted to 1.5 with 10% hydrochloric acid to precipitate honokiol and magnolol. After
133 filtration, the residue was dissolved in ethanol, then the solution was filtered again and
134 evaporated at 30 °C under reduced pressure. The residue was kept in a vacuum for 24 hours
135 to produce a dry crude extract of 258g. The content of honokiol in the crude extract was
136 60.5% by HPLC (Fig.1).

137 [Insert Fig. 1]

138 *2.4 CCC separation procedure*

139 The solvent system *n*-hexane-ethyl acetate-ethanol-water (5:2:5:2, v:v:v:v) was developed as
140 a part of a Chinese FDA submission report for honokiol production required for clinical
141 research. In this study the upper and lower phases were made separately using solvent ratios
142 determined by GC analysis (see Table S1 in Supplementary material). The column was filled

143 with lower (stationary) phase, then the rotor speed was set at 1250 rpm (192g), and the upper
144 (mobile) phase was pumped into the column to establish hydrodynamic equilibrium at 50
145 mL/min in normal phase (NP) mode. Then the sample solution was injected and elution
146 started, which was monitored with an UV detector at 254 nm and 50 mL volume fractions
147 were collected. The volume of stationary phase in each fraction was recorded to establish a
148 stationary phase stripping characteristic against time. For each fraction, 100 μ L of upper and
149 lower phases were pipetted into separate tubes and 900 μ L acetonitrile was added to dilute
150 them for further HPLC analysis. The honokiol yield was calculated by the equation:

151
$$\text{Yield} = \text{Peak area of combined fractions} / \text{peak area of all fractions}$$

152 For each CCC separation, the cycle time was calculated taking into account that the
153 filling/equilibrating stage takes 15 min so that the throughput could be calculated accurately.
154 In all results the throughput and yield is for a honokiol purity of >99% and of a magnolol
155 content of <0.1%.

156

157 **3. Results and discussion**

158 *3.1 Initial stationary phase retention*

159 It is well known that successful separation in CCC is directly related to stationary phase
160 retention (S_f) [24]. The higher the S_f value the better chance for compounds to be well
161 separated at high sample loading. In turn, the former is dependent on rotational speed (or g -
162 field level) of the column and mobile phase flow rate. The higher the rotational speed and
163 the lower the flow rate the higher stationary phase retention. Therefore, the balance
164 between the two allows the optimum S_f to be achieved. The rotational speed range at which
165 a CCC instrument can be operated is generally defined by the CCC manufacturer, while
166 mobile phase choice has no technical restrictions. Du et al [24] demonstrated a linear
167 relationship between the square root of mobile phase flow rate (\sqrt{F}) and retention of
168 stationary phase for a variety of two phase solvent systems run with the lower phase mobile
169 (the lower phase was not aqueous for all the systems therefore, the term “reversed phase
170 mode” has not been used). However, linearity is not always the case, especially when upper
171 phase is used as the mobile phase [25]. It can be seen from Fig. 2 that the Du plot for
172 HEEW at system used in this study is not linear after 50 mL/min ($\sqrt{F} \sim 7$). Therefore, a 30-50
173 mL/min range of flow rate was chosen for further experiments.

174 [Insert Fig. 2]

175 *3.2 Effect of injection flow rate*

176 Working at its best, as a preparative technology, CCC is generally used with high sample
177 loadings, which is achieved by a combination of high concentration and high volume
178 sample solutions. As a consequence of this, it often leads to the additional loss of stationary
179 phase after injecting the sample solution because the latter has very different physico-
180 chemical properties (density & viscosity) to the solvent system itself. When a highly
181 concentrated sample is injected into a column, it is seen as a third phase [21] leading to a
182 loss of stationary phase until the sample is sufficiently diluted by the solvent system. To
183 help this dilution process the injection flow rate can be lowered and maintained low for
184 some time after injection has been completed.

185 The effect of injection flow rate (F_{inj}) on the retention of stationary phase and the separation
186 at fixed sample volume are shown in Fig. 3 and Fig. 4. When the mobile phase flow rate of
187 50 mL/min was kept throughout the run the 50 mL (5.5% of column volume) sample injection
188 led to a 57.4% drop in S_f value from the initial 83.4% (after column equilibration) down to
189 26.0%. As a consequence, the resolution between HK and MG was only 1.1, in other words,
190 they co-eluted. When injection flow rate decreases from 50 to 10 mL/min, the retention of
191 stationary phase and separation is improved. The 18.7% drop in S_f value at 10 mL/min gave
192 peak resolution of 1.3. Complete peak resolution of 1.6 can be achieved at F_{inj} of 1.0 mL/min.
193 Further decrease in F_{inj} did not make any difference in S_f value or resolution but the
194 separation time becomes impractical. While lowering injection flow rate reduces loss of
195 stationary phase and increases resolution and yield, it will also reduce throughput. For
196 example, as injection flow rate changes from 50, 10, 1.0 to 0.1 mL/min, throughput in g/h
197 (yield%) in each case changes respectively as follows: 3.05 (82.1%), 2.85 (98.7%), 1.64
198 (99.8%) and 0.32 (99.9%). This suggested that injection flow rates either side of 10 ml/min
199 (5, 10 and 20 ml/min) would be optimal for further experiments.

200 [Insert Fig. 3]

201 [Insert Fig. 4]

202 *3.3 Optimization of mobile phase and injection flow rates and sample concentration and* 203 *volume*

204 Based on the above results, the affects of mobile phase flow rate (F - 30, 40, 50 mL/min),
205 sample injection flow rate (F_{inj} - 5, 10, 20 ml/min), sample concentration (SC – 100, 120, 140
206 mg/mL) and sample volume (SV – 50, 75, 100 mL) on throughput (g/h) were studied to give
207 a purity of Honokiol of >99% with less than 0.1% of magnolol . Sample temperature was
208 excluded because its increase in 30-60 °C range made the separation marginally worse
209 (results are not shown). The parameters, levels and results are given in Table 1.

210 [Insert Table 1]

211 Experiments 3, 4, 7 and 8 had the highest sample loading of 1.1-1.5 g/100 mL column volume
212 at 100-140 mg/mL concentration injected in 8-11% of column volume (V_c). In all these runs
213 stationary phase was completely lost after sample injection even when the injection flow rate
214 was as low as 5 mL/min. Experiments 6 & 9 gave the best results with a throughput of 3.11
215 and 3.09 g/h respectively, but this was not much better than our original experiment (Table
216 1) which had a throughput of 3.05 g/h. Yield levels from these experiments were 97.4%, 95.9%
217 and 82% respectively. As we were looking for a step change we explored further injection
218 optimisation by changing the injection solution as discussed in the next section.

219 *3.4 Further optimization of the injection procedure*

220 CCC technology is well known for high loading due to higher solubility in a mixture of
221 solvents composing a two-phase system. To maintain reproducibility for preparative and pilot
222 scale separations it is better to make a sample solution in one phase only (even if it gives a
223 suspension) rather than in a mixture of upper and lower phases. Another approach developed
224 by the authors was to dissolve the sample in the best solvent from the solvent system used
225 and then carefully add the rest of the solvents in ratios proportional to the phase composition.
226 All these approaches have been used in this study. Yet the highest throughput achieved was
227 3.1 g/h.

228 Traditionally any solvent system is built around the “best” solvent from a sample solubility
229 point of view. Therefore, the idea to push back the bounds of expectation was to apply this
230 approach directly to the sample solution and make it in the best solvent only. From hexane,
231 ethyl acetate, ethanol and water of the HEEWat solvent system used in this study, ethanol
232 provides the highest solubility for Honokiol crude extract at a concentration of up to 600
233 mg/mL in comparison with 140 mg/mL in the case of using lower phase of the HEEWat
234 while sample solution remains homogeneous.

235 The results shown in Table 1 indicate that loadings above 9 g in various combinations of
236 sample concentration and volume destroys the solvent system in the column and causes a
237 complete loss of stationary phase. Therefore, 9 g loading at 600 mg/mL sample concentration
238 was chosen for the following experiments aiming to keep the volume of ethanol injected into
239 the column to a minimum. Injecting 9 g of sample dissolved in 15 mL of ethanol led to a
240 67.4% drop in Sf value from the initial 96% to a final 28.6% providing partial separation.
241 While injecting 9 g made in the HEEWat lower phase (giving a suspension) caused a
242 complete stripping of stationary phase (from the initial 94% to a final 5.1%) with no
243 separation occurring (the graphical data are given in the Supplementary materials – Figure
244 S1). These results confirmed that there is a possibility of further increasing throughput by
245 adjusting the injection procedure of sample solution in ethanol.

246 It was considered to split injection into two stages and study each one of them separately.
247 The first stage is the loading/injecting of a sample onto the column; the second is the post-
248 loading/injection time and flow rate allowing sample to be diluted even more.

249 [Insert Fig. 5]

250 The importance of the second stage can be seen from Fig. 5. When the injection flow rate
251 was kept at 1 mL/min for 5 more minutes after the sample had been loaded onto the column,
252 the final Sf value improved from 29% to 43% providing a better separation. Therefore,
253 various combinations of duration/flow rate were tested but the volume of the injected sample
254 was kept the same.

255 The duration of the first (injection) stage was cut to the minimum while the second (post-
256 injection) stage was gradually extended (see Table 2). Interestingly, injecting the ethanol
257 sample for 18 seconds at the same flow rate as for equilibrating (50 mL/min) did not affect
258 the stationary phase (SP) retention because the flow rate was dropped afterwards down to 1.0
259 mL/min for 10 min. This allowed the highly concentrated sample to get diluted in the column
260 without causing too much loss of SP resulting in a 91.4% yield and 3.81 g/h throughput.
261 Further extending post-injection time improved peak resolution and also allowed an increase
262 in the sample loading. The latter was done via injecting a larger volume because 600 mg/mL
263 was the solubility limit for the honokiol extract solution in ethanol. When sample mass was
264 increased to 11 g, the throughput of honokiol reached 4.17 g/h. Whereas a 12 g injection led
265 to a reduced yield of 72.2% even with the extended post-loading stage.

266 A final improvement of throughput can be obtained by collecting only the central part of
267 peaks, in other words, by cutting “the peak tail” which contains a low concentration of the
268 target. As shown in Fig. 6 stopping separation at 49.4 min. will give the highest throughput
269 of 4.47 g/h with yield of 85.5%.

270 It should be noted that the fractogram in Fig. 6 obtained for an 11 g loading under the
271 optimized conditions caused the honokiol peak to be non-Gaussian in comparison with the
272 earlier fractogram shown in Fig. 4 for a 6 g loading. This demonstrates that the solvent

273 system/column were running in non-equilibrium conditions while still providing a good
274 throughput & yield. Also the solvent consumption of mobile phase and stationary phase per
275 gram of honokiol was decreased dramatically by 40.2% (from 0.68 L/g to 0.41 L/g) and 48.4%
276 (from 0.40 L/g to 0.21 L/g) respectively.

277 [Insert Table 2]

278 [Insert Fig. 6]

279

280 **4. Conclusions**

281 This research is based on optimizing an injection procedure as a separate process by splitting
282 it into injection and post-injection stages, and applying “the best solvent” approach to the
283 sample solution. This allowed the sample loading to be increased by 1.83 times (from 0.66
284 g/100mL V_c to 1.21 g/100mL V_c) and reach non-equilibrium conditions for the target peak.
285 The Honokiol crude extract was dissolved in ethanol at 600 mg/mL concentration and
286 successfully separated with a hexane-ethyl acetate-ethanol water (5:2:5:2) system in normal
287 phase. Developing a separate flow rate “programme” for the injection stage led to an increase
288 in throughput from 3.05 g/h to 4.47 g/h and in yield from 82.0% to 85.5% while maintaining
289 a Honokiol purity of >99% and Magnolol purity of <0.1%. Further work is required to
290 understand the hydrodynamics of this type of separation process including prediction of
291 operating parameters.

292

293 **5. Acknowledgments**

294 This research was supported by the National Natural Science Foundation of China
295 (81302663), National High Technology Research and Development Program of China (863
296 Program) (2014AA020540) and 2011 Collaborative Innovation Program of China.

297

298 **References**

- 299 [1] L. Chen, Q. Zhang, G. Yang, I. Garrard, S. Ignatova, D. Fisher, I.A. Sutherland, Rapid
300 purification and scale-up of honokiol and magnolol using high-capacity high-speed
301 counter-current chromatography, *J. Chromatogr. A* 1142 (2007) 115-122.
- 302 [2] Y. Lee, D. Choi, S. Han, Y. Kim, K. Kim, Y. Seong, K. Oh, J. Hong, A comparison
303 between extract products of *Magnolia officinalis* on memory impairment and
304 amyloidogenesis in a transgenic mouse model of Alzheimer’s disease, *Biomol. Ther.* 20
305 (2012) 332-339.
- 306 [3] Y. Lee, D. Choi, Y. Yun, S. Han, H. Kim, K. Oh, J. Hong, Ethanol extract of *Magnolia*
307 *officinalis* prevents lipopolysaccharide-induced memory deficiency via its
308 antineuroinflammatory and antiamyloidogenic effects, *Phytother. Res.* 27 (2013) 438-447.
- 309 [4] X. Wu, C. Yu, W. Cai, J. Hua, S. Li, W. Wang, Protective effect of a polyphenolic rich
310 extract from *Magnolia officinalis* bark on influenza virus-induced pneumonia in mice, *J.*
311 *Ethnopharmacol.* 134 (2011) 191-194.


- 312 [5] T. Hirano, M. Gotoh, K. Oka, Natural flavonoids and lignans are potent cytostatic
313 agents against human leukemic HL-60 cells, *Life Sci.* 55 (1994) 1061-1069.
- 314 [6] T. Wang, F. Chen, Z. Chen, Honokiol induces apoptosis through p53-independent
315 pathway in human colorectal cell line RKO, *World J. Gastroenterol.* 10 (2004) 2205-2208.
- 316 [7] S.E. Yang, M.T. Hsieh, T.H. Tsai, S.L. Hsu, Down-modulation of Bcl-XL, release of
317 cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in
318 human squamous lung cancer CH27 cells, *Biochem. Pharmacol.* 63 (2002) 1641-1651.
- 319 [8] X. Wang, X. Duan, G. Yang, X. Zhang, L. Deng, H. Zheng, C. Deng, J. Wen, N. Wang,
320 C. Peng, X. Zhao, Y. Wei, L. Chen, Honokiol crosses BBB and BCSFB, and inhibits brain
321 tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma
322 model, *PloS One*, 6 (2011) e18490.
- 323 [9] X. Bai, F. Cerimele, Honokiol, a small molecular weight natural product, inhibits
324 angiogenesis in vitro and tumor growth in vivo, *J. Biol. Chem.* 278 (2003) 35501-35507.
- 325 [10] R.M. Denton, J.T. Scragg, A.M. Galofre, X.C. Gui, W. Lewis, A concise synthesis of
326 honokiol, *Tetrahedron* 66 (2010) 8029-8035.
- 327 [11] Y. Ito, M. Weinstein, I. Aoki, R. Harada, E. Kimura, K. Nunogaki, The coil planet
328 centrifuge, *Nature* 212 (1966) 985-987.
- 329 [12] A. Marston, K. Hostettmann, Developments in the application of counter-current
330 chromatography to plant analysis, *J. Chromatogr. A* 1112 (2006) 181-194.
- 331 [13] I.A. Sutherland, Recent progress on the industrial scale-up of counter-current
332 chromatography, *J. Chromatogr. A* 1151 (2007) 6-13.
- 333 [14] I.A. Sutherland, D. Fisher, Role of counter-current chromatography in the
334 modernisation of Chinese herbal medicines, *J. Chromatogr. A* 1216 (2009) 740-753.
- 335 [15] R. Hu, Y. Pan, Recent trends in counter-current chromatography, *Trends in Anal.*
336 *Chem.* 40 (2012) 15-27.
- 337 [16] A. Peng, H. Ye, X. Li, L. Chen, Preparative separation of capsaicin and
338 dihydrocapsaicin from *Capsicum frutescens* by high speed counter-current
339 chromatography, *J. Sep. Sci.* 32 (2009) 2967-2973.
- 340 [17] L. Chen, I.A. Sutherland, How to achieve rapid separations in counter-current
341 chromatography, *J. Chromatogr. A* 1114 (2006) 29-33.
- 342 [18] W.D. Conway, Getting started in countercurrent chromatography, in: W.D. Conway
343 (Ed.) *Countercurrent Chromatography: apparatus, theory and applications*, VCH Publishers
344 Inc., New York, 1990, pp. 347-384.
- 345 [19] A. Berthod, B. Billardello, S. Geoffroy, Polyphenols in countercurrent
346 chromatography, An example of large scale separation, *Analisis* 27 (1999) 750-757.
- 347 [20] C-X. Zhao, C-H. He, Sample capacity in preparative high-speed counter-current
348 chromatography, *J. Chromatogr. A* 1146 (2007) 186-192.

- 349 [21] L. Marchal, O. Intes, A. Foucault, J. Legrand, J-M. Nuzillard, J-H. Renault, Rational
 350 improvement of centrifugal partition chromatographic settings for the production of 5-n-
 351 alkylresorcinols from wheat bran lipid extract I. Flooding conditions – optimising the
 352 injection step, J. Chromatogr. A 1005 (2003) 51-62.
- 353 [22] N. Amarouche, L. Boudesocque, C. Sayagh, M. Giraud, J. McGarrity, A. Butte, L.
 354 Marchal, A. Foucault, J-H. Renault, Purification of a modified cyclosporine A by co-
 355 current centrifugal partition chromatography: Process development and intensification, J.
 356 Chromatogr. A 1311 (2013) 72-78.
- 357 [23] M. Blunt, M. Christie, How to predict viscous fingering in three component flow,
 358 Transport in Porous Media 12 (1993) 207-236.
- 359 [24] Q.Z. Du, C.J Wu, G.J. Qian, P.D. Wu, Y. Ito. Relationship between the flow-rate of
 360 the mobile phase and retention of the stationary phase in counter-current chromatography,
 361 J. Chromatogr. A 835 (1999) 231-235.
- 362 [25] P.L. Wood, P. Hewitson, I.A. Sutherland, S.N. Ignatova, Differences in stationary
 363 phase retention between normal phase and reverse phase in J-type centrifuges caused by the
 364 influence of coriolis acceleration, J. Chromatogr. A, submitted for a publication.
- 365 **Legends**
- 366 Figure 1: HPLC chromatogram of *Magnolia officinalis* bark extract and structure of
 367 honokiol and magnolol. HPLC conditions—column: Sunfire C18 column (150mm×4.6mm
 368 I.D., 5 µm); mobile phase: acetonitrile-0.1% formic acid aqueous solution (65:35, v:v);
 369 flow rate: 1ml/min; temperature: 30 °C; detection wavelength:254 nm.
- 370 Figure 2: Du Plot. Conditions: column volume 912 ml; phase system: *n*-hexane-ethyl
 371 acetate-ethanol-water (5:2:5:2, v:v:v:v); NP mode; rotation speed:1250 rpm.
- 372 Figure 3: Effect of different sample injection flow rate on stationary phase retention. For
 373 conditions see section 2.4. Sample: 50 mL, 120 mg/mL in LP HEEWat, NP mode.
- 374 Figure 4: Effect of different sample injection flow rates on separation. For conditions see
 375 section 2.4. Sample: 50 mL, 120 mg/mL in LP HEEWat, NP mode.
- 376 Figure 5: Effect of different injection procedure. For conditions see section 2.4. Sample 15
 377 mL, 600 mg/mL in ethanol, NP mode.
- 378 Figure 6: Fractogram after optimization, showing throughput and yield for a honokiol
 379 purity >99% and magnolol purity <0.1%. Sample volume: 18.3 mL; sample concentration:
 380 600 mg/mL; flow rate of mobile phase: 50 mL/min; injection procedure: 50 mL/min for
 381 0.4min then 1.0 mL/min for 15 min.
- 382 Table 1. Parameters, levels and results in orthogonal experimental design for honokiol and
 383 magnolol purities of >99% and <0.1% respectively.
- 384 Table 2. Final Sf, yield and throughput with different injection procedure and sample mass
 385 for honokiol and magnolol purities of >99% and <0.1% respectively.

386


387

388 Figure 1: HPLC chromatogram of *Magnolia officinalis* bark extract and structure of
 389 honokiol and magnolol. HPLC conditions: column Sunfire C18 column (150mm×4.6mm
 390 I.D., 5 μm); mobile phase: acetonitrile-0.1% formic acid aqueous solution (65:35, v:v);
 391 flow rate: 1ml/min; temperature: 30 °C; detection wavelength:254 nm.




392
 393
 394

395 Figure 2: Du Plot. Conditions: column volume 912 ml; phase system: *n*-hexane-ethyl
 396 acetate-ethanol-water (5:2:5:2, v:v:v:v); NP mode; rotation speed:1250 rpm




397
 398

399 Figure 3: Effect of different sample injection flow rate on stationary phase retention. For
 400 conditions see section 2.4. Sample: 50 mL, 120 mg/mL in LP HEEWat, NP mode.




401
 402

403 Figure 4: Effect of different sample injection flow rates on separation. For conditions see
 404 section 2.4. Sample: 50 mL, 120 mg/mL in LP HEEWat, NP mode.



405


406 Figure 5: Effect of different injection procedure. For conditions see section 2.4. Sample 15
 407 mL, 600 mg/mL in ethanol, NP mode.



408

409

410 Figure 6: Fractogram after optimization, showing throughput and yield for a honokiol
 411 purity >99% and manolol purity <0.1%. Sample volume: 18.3 mL; sample concentration:
 412 600 mg/mL; flow rate of mobile phase: 50 mL/min; injection procedure: 50 mL/min for
 413 0.4min then 1.0 mL/min for 15 min.



414

415 Table 1. Parameters, levels and results in orthogonal experimental design for honokiol and
 416 magnolol purities of >99% and <0.01% respectively.

Experiment No.	Mobile phase F (mL/min)	Injection flow rate (mL/min)	Sample concentration (mg/mL)	Sample volume (mL)	Sample mass (g)	Final Sf (%)	Throughput (g/h)
1	30	5	100	50	5	90	1.30
2	30	10	120	75	9	46	2.68
3	30	20	140	100	14	<5%	0.00
4	40	5	120	100	12	<5%	0.00
5	40	10	140	50	7	44	2.84
6	40	20	100	75	7.5	50	3.11
7	50	5	140	75	10.5	<5%	0.00
8	50	10	100	100	10	<5%	0.00
9	50	20	120	50	6	45	3.09
Original	50	50	120	50	6	26	3.05

417

418 Table 2: Final Sf, yield and throughput with different injection procedure and sample mass
 419 for honokiol and magnolol purities of >99% and <0.01% respectively.

Sample mass (g)	F ₁ (mL/min)	T ₁ (min)	F ₂ (mL/min)	T ₂ (min)	Final Sf (%)	Yield (%)	Throughput (g/h)
9	1	15	/	0	23.6	57.0	2.43
9	1	20	/	0	41.7	88.1	3.17
9	5	3	1	5	35.6	71.9	3.32
9	50	0.3	1	10	40.8	91.4	3.82
11	50	0.4	1	15	35.1	86.8	4.17
12	50	0.4	1	15	29.6	69.4	3.92
12	50	0.4	1	20	27.4	72.2	3.73

420

421

422


423 **Supplementary materials**

424 Table S1. Constituent of different solvents in upper phase and lower phase in HEEWat (5:2:5:2, v/v)
 425 solvent system as measured by GC analysis.

	composition of upper phase (%)	composition of lower phase (%)
n-Hexane	81	6.5
Ethyl acetate	12.9	18.9
Ethanol	6.1	50.5
Water	0	24.2

426

427



428

429 Fig. S1. The effect of different sample solvent to stationary phase stripping. Conditions:
 430 column volume: 912 mL; phase system: *n*-hexane-ethyl acetate-ethanol-water (5:2:5:2,
 431 v:v:v:v); stationary phase: lower aqueous phase; rotation speed:1250 rpm; detection
 432 wavelength: 254 nm; sample volume: 15 mL; sample concentration: 600 mg/mL; flow rate
 433 of mobile phase: 50 mL/min; sample injection flow rate 1.0 mL/min for 15 minutes.

434

435

436